Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second of the two phase I bioequivalence trials of once-daily extended release formulation of lorcaserin in healthy adults

Next Previous
Trial Profile

Second of the two phase I bioequivalence trials of once-daily extended release formulation of lorcaserin in healthy adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorcaserin (Primary) ; Lorcaserin
  • Indications Obesity
  • Focus Pharmacokinetics; Registrational
  • Sponsors Arena Pharmaceuticals; Eisai Inc

    • Most Recent Events

    • 27 Sep 2016 Results assessing pharmacokinetics published in the Clinical Therapeutics.
    • 20 Jul 2016 According to Eisai media release, based on results of this and another phase I trial (CTP 700255707) the US FDA has approved a New Drug Application (NDA) for lorcaserin for chronic weight management.
    • 30 Nov 2015 According to Eisai Inc media release, the US FDA has accepted for filling the New Drug Application (NDA) for extended release lorcaserin based on results of this and another phase I trial (CTP 700255707).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top